Colin Neill

Experience

• 

  PwC

  Jan 1975 - Jan 1983

  Senior Manager
• 

  American Express

  Jan 1983 - Jan 1986

  VP Business Planning; VP Internal Audit
• 

  Clintrials Research, Inc.

  Jan 1998 - Jan 2001

  SVP, CFO, Treasurer and Secretary

  ClinTrials Research, Inc., (NASDAQ: CCRO) is a global contract research organization providing comprehensive preclinical, clinical and post marketing research services, including monitoring, data management and biostatistics, medical and regulatory services to pharmaceutical, biotechnology and medical device clients. Consolidated revenues were over $100 million. Company sold in 2001.• Implemented Board’s mandate to engineer a “soft landing” for the Company, resulting in sale to Inveresk Research International at a price near 52-week high share price. Conducted negotiations and extensive due diligence with three suitors. Key spokesman for shareholder and investor communications. Maintained active relationships with investment analysts. Presented at numerous health care conferences and private investor meetings. Conducted quarterly analyst teleconferences, and participated in all Board of Directors meetings. These efforts raised share price from a Q498 low of $2.34 to $6.00 at time of sale (+156%). • Provided strategic focus to management team and spearheaded M&A activity for acquisitions and divestitures. Spun off pharmacoeconomic business in Chicago and closed South American operations. Analyzed option to purchase preclinical facility in Michigan.• Stabilized cash flow drain by bringing a relentless focus, sense of urgency and attention to detail to company’s cost structure resulting in first year reduced costs of over $7 million. Reduced Days Sales Outstanding (DSO’s) 83 days to 61. Streamlined operations by relocating corporate headquarters from Nashville to North Carolina. Renegotiated and renewed bank line of credit. Generated positive cash flow from operations for past two years despite continuing losses.• Enhanced sales efforts through identification and hiring of President of North American clinical operations. Identified key medical contacts that resulted in collaborative selling ventures. Show less

• 

  Axonyx Inc

  Jan 2003 - Jan 2006

  CFO, Treasurer and Secretary

  AXONYX INC. New York, New York 2003- 2006Chief Financial Officer, Treasurer and Secretary.Reported to Chairman and CEO.Axonyx, Inc, (NASDAQ: AXYX) was a biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds for the treatment of Alzheimer’s disease and other central nervous system disorders.• Lead role in strategic merger / redirection of the Company. Worked closely with CEO and counsel on numerous transactions and potential M&A targets and licensing opportunities. Resulted in successful merger agreement with TorreyPines Therapeutics Inc.• Raised $100 million equity capital, in three separate financings with three investment banks. Market capitalization of Company increased from under $30 million to close to $400 million.• Led the finance and accounting function ensuring all SEC filings made on time, namely Form 10-K, quarterly reports on Form 10-Q, four Form S-3 registration statements and a merger proxy registration on Form S-4.• Accomplished acquisition of a controlling interest in Oxis International Inc (OXIS.OB). Managed transition process and management changes needed at Oxis. Raised additional equity capital of $6.5 million. Served on Oxis board as a director and Chairman of both the audit and nominating committees. • Assessed the internal control environment and successfully led Company through two full Sarbanes-Oxley Section 404 compliance audits as an accelerated filer with the SEC.• Increased Company’s Wall Street visibility by maintaining a very active investor awareness program with Chairman & CEO. Acted as a key spokesman for shareholder and investor communications. Developed and implemented an investor relations program. Presented Company at numerous conferences. Show less

• 

  Oxis International, Inc

  Jan 2004 - Jan 2008

  Board Member and Chair of Audit and Nominating committees
• 

  Pharmos Corporation

  Jan 2006 - Jan 2012

  President and CFO

  Pharmos Corporation (Nasdaq / OTC/ PARS) is a biopharmaceutical company that discovers and develops novel therapeutics to treat a range of diseases of the central nervous system.• Managed all aspects of operating a public company including full profit and loss responsibility. Intense involvement in clinical management for Company’s lead compounds, which resulted in completing trials with available financial resources. • Rapidly downsized operations to ensure cash resources were not wasted. Closed foreign operations and negotiated licensing arrangements for technology.• Implemented an outsourcing model. Identified, hired and managed a wide array of outsourced scientific and clinical consultants and patent counsel to make formerly fixed costs variable.• Prepared and presented material, including strategy and operational updates, frequently to Board. Led two financing rounds in a tight financing environment which provided sufficient capital to complete major clinical trial.• Led the finance and accounting function ensuring effective completion of all SEC filings, Sarbanes Oxley compliance, registration statements, annual shareholder meetings, shareholder communications and presentations, press releases, web site maintenance Show less

• 

  Galectin Therapeutics, Inc

  Jan 2007 - Jan 2011

  Board Member and member of Audit Committee
• 

  Children's Medical Research Foundation, Inc ( CMRF, Inc)

  Jul 2013 - Dec 2023

  Board Member

  CMRF supports the work of the Children's Hospital in Crumlin, Dublin, Ireland. This is the foremost paediatric hospital in Ireland.

• 

  Boston Therapeutics Inc.

  Dec 2013 - Sept 2019

  Board Member and Chair of Audit Committee
• 

  Evergreen Cemetery & Crematory

  Apr 2018 - now

  Board Member

  Historical cemetery in Hillside, NJ, dating from circa 1850.

• 

  Union County Savings Bank

  Apr 2020 - now

  Board Member